ScottHuntingtonMDMPH, MSHP

PubMed

• 22 citations
  Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study
  Rong Wang, Amer M. Zeidan, James B. Yu, Pamela R. Soulos, Amy J. Davidoff
  The Prostate. 2017-04-01
• 79 citations
  Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells.
  Andrew G. Evans, Paul G. Rothberg, W. Richard Burack, Scott F. Huntington, David L. Porter
  British Journal of Haematology. 2015-06-18
• 6 citations
  Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.
  Rong Wang, Rory M Shallis, Jessica M Stempel, Scott F Huntington, Amer M Zeidan
  Blood Advances. 2023-03-14

Abstracts/Posters

• Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neopl...
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United State...
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/...
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Populatio...
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Populati...
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and ...
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018